ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 0682

Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study

Alex Luta1, Saloni Mitchell2 and Virginia Steen3, 1Hospital for Special Surgery, New York, NY, 2Mount Sinai West and Morningside, New York, NY, 3Georgetown University School of Medicine, Washington, DC

Meeting: ACR Convergence 2025

Keywords: prognostic factors, Renal, risk factors, Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, October 26, 2025

Title: (0671–0710) Systemic Sclerosis & Related Disorders – Clinical Poster I

Session Type: Poster Session A

Session Time: 10:30AM-12:30PM

Background/Purpose: Scleroderma Renal Crisis (SRC) is a severe manifestation of Systemic Sclerosis (SSc) associated with elevated morbidity and mortality. We aimed to address the challenges of studying this rare condition by collecting and analyzing data to further our understanding of SRC. This research builds upon our previous work presented at ACR in 2022. We previously found that patients who did not have a diagnosis of SSc before SRC had a statistically significant higher odds of requiring hemodialysis (HD) during SRC compared to patients who had a prior diagnosis of SSc. We also found that patients with a history of hypertension (HTN) had a statistically significant higher odds of 1-year mortality compared to patients without HTN. We did not find any statistically significant increase in the odds of severe outcomes in SRC for African-American patients, patients with RNA Polymerase III antibodies, or patients with late SRC.

Methods: We obtained data through chart review of 44 patients at our institution who developed SRC between 2008 and 2020. All patients met ACR/EULAR 2013 classification criteria for SSc. We evaluated predictors of HD at time of SRC and 1-year mortality post-SRC using Fisher’s exact tests and Wilcoxon rank-sum tests, and we reported related p-values.

Results: Table 1 includes selected characteristics of our patients with SRC. We found that patients who required HD at time of SRC had a statistically significant elevation in creatinine and decreases in platelet count and hemoglobin, compared to patients who did not require HD (Table 2). While there were no statistically significant differences regarding HD need at time of SRC based on sex, specialist care, or presence of schistocytes on peripheral blood smear (PBS), there were trends toward statistical significance. Furthermore, we found statistically significant differences in 1-year mortality based on patient sex and age (Table 3). Male sex and older age were associated with 1-year mortality, which supports previously reported findings (1). There was not a statistically significant difference in 1-year mortality between patients on HD 6 months-post SRC and those who were not on HD 6 months-post SRC.

Conclusion: We identified statistically and clinically significant differences in SRC lab parameters between patients who required HD at SRC and those who did not. The median creatinine and hemoglobin levels differed by over one unit, and thrombocytopenia was a predictor of HD requirement at SRC. Because there were trends toward statistical significance for sex, specialist care, and presence of schistocytes regarding HD requirement, we hope to reevaluate these potential predictors on larger datasets. We found that older age and male sex were associated with elevated 1-year mortality. Combining these results with our previous findings, we have identified several predictors of severe outcomes in SRC. These findings can assist clinicians with risk-stratification of SRC patients, lay the groundwork for future research, and help mitigate severe outcomes.1. Steen VD, Medsger TA Jr. Long-term outcomes of scleroderma renal crisis. Ann Intern Med. 2000 Oct 17;133(8):600-3. doi: 10.7326/0003-4819-133-8-200010170-00010. PMID: 11033587.

Supporting image 1Legend: SSc = Systemic Sclerosis, also known as Scleroderma, Anti-RNA Polymerase III (+) = Patients

who tested positive for the Anti-RNA Polymerase III antibody, SRC = Scleroderma Renal Crisis,

Late SRC = Patients with at least 4 years between first SSc symptom and SRC. The mean age of

patients was 51.5, and the ages of patients ranged from 27 to 88 years old.

Supporting image 2Legend: SRC = Scleroderma Renal Crisis, HD = Hemodialysis, Dx = Diagnosis, Specialist Care = Patients

under the care of a rheumatologist with Scleroderma expertise, Schistocytes = Presence of schistocytes

on a peripheral blood smear at the time of Scleroderma Renal Crisis diagnosis. For continuous variables,

median and interquartile range (Q1 and Q3) are reported. For categorical variables, proportions (%) are

reported. Statistically significant P-values are bolded. *One patient had missing data regarding dialysis

need at Scleroderma Renal Crisis Presentation.

Supporting image 3Legend: SRC = Scleroderma Renal Crisis, HD = Hemodialysis. For continuous variables,

median and interquartile range (Q1 and Q3) are reported. For categorical variables,

proportions (%) are reported. Statistically significant P-values are bolded. *One patient had

missing data regarding 1-year mortality after Scleroderma Renal Crisis.


Disclosures: A. Luta: SurgiBox, Inc., 12,; S. Mitchell: None; V. Steen: None.

To cite this abstract in AMA style:

Luta A, Mitchell S, Steen V. Predictors of Severe Outcomes in Scleroderma Renal Crisis: Updated Results from a Single Center Study [abstract]. Arthritis Rheumatol. 2025; 77 (suppl 9). https://acrabstracts.org/abstract/predictors-of-severe-outcomes-in-scleroderma-renal-crisis-updated-results-from-a-single-center-study/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2025

ACR Meeting Abstracts - https://acrabstracts.org/abstract/predictors-of-severe-outcomes-in-scleroderma-renal-crisis-updated-results-from-a-single-center-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology